Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atu027 and Gemcitabine in Advanced Pancreatic Adenocarcinoma
NCT01808638Phase 2Completed
- Sponsor
- Silence Therapeutics
- Start
- Mar 2013
- Primary completion
- Aug 2015
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of Atu027 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Silence Therapeutics. Started Mar 2013; status: completed.
02
Drugs
Atu027
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01808638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808638.